Evidence map›Paper›PMID 35428209›Full record

ArticleBMC infectious diseases2022

Low CD4/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters: results from a multicentre cohort study, 2004-2018.

Lourdes Domínguez-Domínguez, Marta Rava, Otilia Bisbal, Luis Lopez-Cortés, Joaquín Portilla, Daniel Podzamczer, Julián Olalla, Daniel Fuster, Rafael Rubio, Inmaculada Jarrín and 3 more

Abstract readMulticenter Study
In one paragraph

Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lourdes Domínguez-Domínguez *Unidad Infección VIH, Hospital Universitario 12 de Octubre, Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
Marta Rava *Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Avda. Monforte de Lemos 5, 28029, Madrid, Spain. mrava@isciii.es.ORCID http://orcid.org/0000-0003-2260-9370
Otilia BisbalUnidad Infección VIH, Hospital Universitario 12 de Octubre, Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
Luis Lopez-CortésCIBER de Enfermedades Infecciosas (CIBERInfec), Madrid, Spain.
Joaquín PortillaHospital General Universitario de Alicante/Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana/Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain.
Daniel PodzamczerUnidad VIH, Servicio de Enfermedades Infecciosas, IDIBELL-Hospital Universitari de Bellvitge, Barcelona, Spain.
Julián OlallaUnidad de Medicina Interna, Hospital Costa del Sol, Marbella, Spain.
Daniel FusterServicio de Medicina Interna, Unidad de Adicciones, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Redes de Investigación Cooperativa Orientadas al Resultado en Salud (RICORS) RD21/0009/0004, Badalona, Spain.
Rafael RubioUnidad Infección VIH, Hospital Universitario 12 de Octubre, Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
Inmaculada JarrínCentro Nacional de Epidemiología, Instituto de Salud Carlos III, Avda. Monforte de Lemos 5, 28029, Madrid, Spain.
José Antonio Iribarren *Hospital Universitario de Donostia, IIS Biodonostia, San Sebastián, Spain.
Santiago Moreno *CIBER de Enfermedades Infecciosas (CIBERInfec), Madrid, Spain.
Cohort of the Spanish HIV/AIDS Research Network (CoRIS)

Funding

Instituto de Salud Carlos III RD06/006Instituto de Salud Carlos III RD12/0017/0018Instituto de Salud Carlos III RD16/0002/0006
6 · The paper itself

Abstract

backgroundTo study whether the association between the CD4/CD8 ratio variation over time and the development of clinical outcomes vary in late presenters (CD4 count < 350/µL or AIDS event at enrolment) or advanced presenters (CD4 count < 200/µL or AIDS event at enrolment).

methodsWe included ART-naïve adults from the Cohort of the Spanish HIV/AIDS Research Network (CoRIS) enrolled between January 2004 up to November 2018 and with at least 6 months of follow-up. We used extended Cox proportional hazard models to estimate the hazard ratios (HRs) for the association between CD4/CD8 ratio over time and a composite endpoint of the occurrence of the first AIDS event, first serious non-AIDS event or overall mortality occurring from 6 months after enrolment. HRs in non-late, late and advanced presenters were obtained by including an interaction term between late presentation status and CD4/CD8 ratio over time.

resultsOf 10,018 participants, 55.6% were late presenters and 26.5% were advanced presenters. Compared with CD4/CD8 ratio > 0.4, CD4/CD8 ratio ≤ 0.4 over time was associated with an increased risk of experiencing the composite endpoint in non-late (HR 1.90; 95%CI 1.48, 2.43), late (HR 1.94; 1.46, 2.57) and advanced presenters (HR 1.72; 1.26, 2.34). Similarly, CD4/CD8 ratio ≤ 0.4 over time was associated with a higher risk of developing an AIDS event (HR 3.31; 2.23, 4.93 in non-late; HR 2.75; 1.78, 4.27 in late and HR 2.25; 1.34, 3.76 in advanced presenters) or serious non-AIDS event (HR 1.39; 0.96, 2.02 in non-late, HR 1.62; 1.10, 2.40 in late and HR 1.49; 0.97, 2.29 in advanced presenters) as well as with a higher risk of overall mortality (HR 1.49; 0.92, 2.41 in non-late, HR 1.80; 1.04, 3.11 in late and HR 1.61; 0.92, 2.83 in advanced presenters) compared to CD4/CD8 > 0.4, regardless of the late presentation status.

conclusionsA low CD4/CD8 measured over time is associated with increased risk of morbidity and mortality in people living with HIV independently of their late presentation status. These data support the prognostic role of CD4/CD8 over time and can help defining a subgroup of patients who need closer monitoring to avoid comorbidities.

Indexed as

Acquired Immunodeficiency SyndromeHIV InfectionsAdultCD4 Lymphocyte CountCD8-Positive T-LymphocytesCohort StudiesHumansMorbidityAIDS eventsCD4/CD8Clinical outcomesLate presentationMortalitySerious non-AIDS events

Identifiers

PMID35428209
PMCPMC9013070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.